INmune Bio (NASDAQ:INMB) Announces Quarterly Earnings Results

INmune Bio (NASDAQ:INMB) released its earnings results on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is moving toward regulatory filing — the company completed a rapid-assessed PIP, started process‑validation manufacturing runs, signed a supply agreement with Anthony Nolan for umbilical cords, and expects to submit the U.K. MAA in early Q3 as it aims for commercial manufacture in 2027.
• XPro development continues with additional MINDFuL imaging analyses (MRI myelin preservation and structural integrity) and the company is exploring rare‑disease trials and partner options to define late‑stage/regulatory paths.
• Operational spending fell this quarter, with net loss narrowing to approximately $5.4 million (from $9.7M) and R&D down to ~$3.6M (from $7.6M), reflecting lower burn compared with the prior year period.
• Cash and equivalents were approximately $21.4 million at March 31, 2026, which management says funds operations only through Q1 2027, indicating a near‑term need for additional financing or partnerships to support commercialization and late‑stage programs.

INmune Bio Stock Performance

Shares of NASDAQ:INMB traded down $0.09 during midday trading on Thursday, hitting $1.43. 311,985 shares of the company’s stock traded hands, compared to its average volume of 244,408. The company has a market cap of $38.01 million, a PE ratio of -0.75 and a beta of 1.04. The firm’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $1.53. INmune Bio has a twelve month low of $1.09 and a twelve month high of $11.64.

Hedge Funds Weigh In On INmune Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its holdings in shares of INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after acquiring an additional 20,121 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after acquiring an additional 66,700 shares in the last quarter. State Street Corp lifted its holdings in shares of INmune Bio by 22.3% during the 4th quarter. State Street Corp now owns 347,259 shares of the company’s stock valued at $542,000 after acquiring an additional 63,426 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of INmune Bio by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after acquiring an additional 28,541 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of INmune Bio during the 4th quarter valued at $26,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.00.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.